Comparison 4. Thoracic semeiologic alterations (AC versus placebo).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Thoracic semeiologic alterations after 5 days	2	109	Risk Difference (M‐H, Fixed, 95% CI)	‐0.06 [‐0.13, 0.02]
2 Thoracic semeiologic alterations after 5 days	2	109	Risk Difference (M‐H, Random, 95% CI)	‐0.05 [‐0.20, 0.10]
3 Thoracic semeiologic alterations after 5 days	2	109	Risk Ratio (M‐H, Fixed, 95% CI)	0.14 [0.01, 2.63]
4 Thoracic semeiologic alterations at the end of treatment (= 28 days)	1	100	Risk Difference (M‐H, Fixed, 95% CI)	‐0.14 [‐0.25, ‐0.03]
4.1 Subgroup = bronchitis	1	48	Risk Difference (M‐H, Fixed, 95% CI)	‐0.11 [‐0.27, 0.06]
4.2 Subgroup = tracheitis	1	52	Risk Difference (M‐H, Fixed, 95% CI)	‐0.17 [‐0.32, ‐0.02]
5 Thoracic semeiologic alterations at the end of treatment (= 28 days)	1	100	Risk Ratio (M‐H, Fixed, 95% CI)	0.17 [0.03, 0.99]
5.1 Subgroup = bronchitis	1	48	Risk Ratio (M‐H, Fixed, 95% CI)	0.26 [0.03, 2.32]
5.2 Subgroup = tracheitis	1	52	Risk Ratio (M‐H, Fixed, 95% CI)	0.11 [0.01, 1.95]